Home > Healthcare > Medical Devices > Diagnostic Devices > Hepatitis E Diagnostic Tests Market
Hepatitis E Diagnostic Tests Market Trends
- Report ID: GMI10834
- Published Date: Aug 2024
- Report Format: PDF
Hepatitis E Diagnostic Tests Market Trends
- Rising awareness and the adoption of comprehensive screening programs are key factors driving market growth.
- Public health campaigns and educational efforts have increased awareness about hepatitis E, motivating individuals to seek testing and diagnosis. Expanded screening programs, particularly in high-risk regions, are improving the ability to detect and manage the disease more effectively. These initiatives not only facilitate early diagnosis but also help track prevalence and control the spread of hepatitis.
Frequently Asked Questions (FAQ) :
Hepatitis E diagnostic tests market size was valued at USD 60 million in 2023 and is estimated to grow at 4.3% CAGR from 2024 to 2032 due to rising awareness and screening programs.
The hospitals segment in the market accounted for USD 25.7 million in 2023 as they often serve as central hubs for patient care.
The U.S. hepatitis E diagnostic tests market is projected to reach USD 34.2 million by 2032 led by advances in diagnostic technologies and the rise of point-of-care testing.
altona Diagnostics GmbH, CTK Biotech, Inc., Dia.Pro Diagnostic Bioprobes s.r.l, DiaSorin S.p.A., ELITechGroup (Bruker company), F. Hoffmann-La Roche Ltd, Fortress Diagnostics, Genscript Biotech Corporation, and Guangzhou Wondfo Biotech Co., Ltd.
Hepatitis E Diagnostic Tests Market Scope
×
Get a free sample of
Hepatitis E Diagnostic Tests Market
Inquiry Before Buying
Get special pricing options on this report
Request Sectional Data
Over 70% of our clients customize reports to fit their needs. Please tell us how you would like to customize yours
below